I-Mab (IMAB)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
I-Mab (IMAB) with AI Score 39/100 (Weak). I-Mab is a clinical-stage biopharmaceutical company focused on developing innovative biologics for cancer and autoimmune diseases. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 17, 2026I-Mab (IMAB) Healthcare & Pipeline Overview
I-Mab is a clinical-stage biopharmaceutical company specializing in the discovery, development, and commercialization of biologics for cancer and autoimmune disorders. With a diverse pipeline of drug candidates in clinical trials and strategic collaborations with major pharmaceutical companies, I-Mab aims to address unmet medical needs in the global healthcare market.
Investment Thesis
I-Mab presents a notable research candidate due to its diverse pipeline of clinical-stage biologics targeting significant unmet medical needs in oncology and autoimmune diseases. The company's strategic collaborations with major pharmaceutical companies like AbbVie and Roche Diagnostics validate its technology and provide potential revenue streams. Key value drivers include the successful advancement of lead drug candidates, such as Felzartamab and Lemzoparlimab, through clinical trials and regulatory approvals. The company's market capitalization of $0.24 billion, combined with a high beta of 1.46, suggests potential for significant returns, although it also indicates higher volatility. A key risk is the inherent uncertainty in drug development, including potential clinical trial failures and regulatory hurdles. The company's P/E ratio of -30.83 reflects its current lack of profitability, which is typical for clinical-stage biopharmaceutical companies.
Based on FMP financials and quantitative analysis
Key Highlights
- I-Mab is developing Felzartamab, a CD38 antibody, currently in Phase 1b/2a clinical trials for the treatment of membranous nephropathy.
- Eftansomatropin alfa, a long-acting human growth hormone, has completed Phase 3 clinical trials for pediatric growth hormone deficiency.
- Lemzoparlimab, a CD47 monoclonal antibody, has completed Phase 2 clinical trials, demonstrating potential in oncology.
- I-Mab has established strategic collaborations with AbbVie, Sinopharm, PT Kalbe Genexine Biologics, and Roche Diagnostics.
- The company's pipeline includes multiple drug candidates targeting cancer and autoimmune diseases, addressing significant unmet medical needs.
Competitors & Peers
Strengths
- Diverse pipeline of clinical-stage drug candidates.
- Strategic collaborations with major pharmaceutical companies.
- Proprietary drug development platform for biologics.
- Experienced management team.
Weaknesses
- Lack of profitability as a clinical-stage company.
- High reliance on clinical trial outcomes and regulatory approvals.
- Limited commercial infrastructure.
- Geographic concentration in China.
Catalysts
- Upcoming: Data readout from Phase 1b/2a clinical trial of Felzartamab for membranous nephropathy.
- Upcoming: Regulatory approval decision for Eftansomatropin alfa for pediatric growth hormone deficiency.
- Ongoing: Advancement of Lemzoparlimab through clinical trials in oncology.
- Ongoing: Expansion of strategic collaborations with pharmaceutical companies.
Risks
- Potential: Clinical trial failures and regulatory setbacks for drug candidates.
- Potential: Competition from established pharmaceutical companies and emerging biotech firms.
- Ongoing: Changes in healthcare regulations and reimbursement policies.
- Ongoing: Economic downturns and market volatility.
- Potential: Currency risk associated with investing in an ADR.
Growth Opportunities
- Expansion of Felzartamab into additional indications: Felzartamab, currently in Phase 1b/2a trials for membranous nephropathy, has the potential to be expanded into other CD38-related autoimmune diseases. The market for autoimmune disease therapies is substantial, with a global market size estimated at $120 billion. Successful clinical trials and regulatory approvals in additional indications could significantly increase the drug's market potential and drive revenue growth for I-Mab. This expansion could occur within the next 3-5 years, pending clinical trial outcomes.
- Commercialization of Eftansomatropin alfa for pediatric growth hormone deficiency: Eftansomatropin alfa, a long-acting human growth hormone that has completed Phase 3 clinical trials, represents a near-term commercial opportunity for I-Mab. The market for growth hormone deficiency therapies is estimated at $4 billion globally. Successful regulatory approval and commercial launch of Eftansomatropin alfa could generate significant revenue for the company. This opportunity is expected to materialize within the next 1-2 years, pending regulatory review and approval.
- Advancement of Lemzoparlimab in oncology: Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trials, holds promise as a novel cancer immunotherapy. The market for cancer immunotherapies is rapidly growing, with a global market size estimated at $40 billion. Further clinical development and regulatory approval of Lemzoparlimab could position I-Mab as a key player in the oncology market. This opportunity is expected to unfold over the next 3-5 years, contingent on clinical trial results.
- Strategic collaborations with pharmaceutical companies: I-Mab's existing collaborations with AbbVie, Sinopharm, PT Kalbe Genexine Biologics, and Roche Diagnostics provide access to resources, expertise, and market access. Expanding these collaborations or establishing new partnerships could accelerate the development and commercialization of I-Mab's drug candidates. Strategic alliances are crucial in the biotechnology industry, allowing companies to share risks and rewards. This is an ongoing opportunity with no specific timeline.
- Development of novel biologics for autoimmune diseases: I-Mab's focus on developing innovative biologics for autoimmune diseases aligns with the growing prevalence of these conditions and the increasing demand for effective therapies. The company's pipeline includes several drug candidates targeting autoimmune indications, such as Felzartamab and Plonmarlimab. Continued investment in research and development could lead to the discovery and development of novel therapies that address unmet medical needs. This is a long-term growth opportunity with ongoing research and development efforts.
Opportunities
- Expansion of existing drug candidates into new indications.
- Commercialization of approved drugs in global markets.
- Establishment of new strategic collaborations.
- Development of novel biologics for unmet medical needs.
Threats
- Clinical trial failures and regulatory setbacks.
- Competition from established pharmaceutical companies.
- Changes in healthcare regulations and reimbursement policies.
- Economic downturns and market volatility.
Competitive Advantages
- Proprietary drug development platform for biologics.
- Strong intellectual property portfolio protecting its drug candidates.
- Strategic collaborations with leading pharmaceutical companies.
- Experienced management team with expertise in drug development and commercialization.
About IMAB
Founded in 2014 and headquartered in Shanghai, China, I-Mab is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative biologics for the treatment of cancer and autoimmune diseases. The company's mission is to bring transformative medicines to patients worldwide through a combination of internal research and development efforts and strategic partnerships. I-Mab's pipeline includes a diverse portfolio of drug candidates in various stages of clinical development, targeting a range of oncology and autoimmune indications. Key programs include Felzartamab, a CD38 antibody in Phase 1b/2a trials for membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone that has completed Phase 3 clinical trials for pediatric growth hormone deficiency; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trials. The company also has several other promising drug candidates in earlier stages of development, including Enoblituzumab, Efineptakin, TJ210, Plonmarlimab, and Uliledlimab. I-Mab has established strategic collaborations with leading pharmaceutical companies, including AbbVie, Sinopharm, PT Kalbe Genexine Biologics, and Roche Diagnostics, to accelerate the development and commercialization of its drug candidates. With a focus on innovation and a commitment to addressing unmet medical needs, I-Mab is poised to make a significant impact on the future of healthcare.
What They Do
- Discovers and develops innovative biologics for cancer and autoimmune disorders.
- Conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
- Seeks regulatory approvals from agencies such as the FDA and EMA.
- Commercializes its approved drugs through partnerships and internal sales efforts.
- Engages in strategic collaborations with pharmaceutical companies to accelerate drug development.
- Focuses on addressing unmet medical needs in oncology and autoimmune diseases.
- Utilizes advanced technologies and research methods to discover novel drug targets.
Business Model
- Develops and patents novel biologics for cancer and autoimmune diseases.
- Out-licenses or co-develops its drug candidates with pharmaceutical partners.
- Generates revenue through milestone payments, royalties, and product sales.
- Invests in research and development to expand its pipeline of drug candidates.
Industry Context
The biotechnology industry is characterized by high growth potential driven by innovation in drug development and increasing demand for novel therapies. I-Mab operates in a competitive landscape that includes established pharmaceutical companies and emerging biotech firms. The company's focus on biologics and strategic collaborations positions it to capitalize on market trends such as the growing adoption of targeted therapies and the increasing prevalence of cancer and autoimmune diseases. The biotechnology industry is expected to continue its growth trajectory, driven by advancements in genomics, proteomics, and personalized medicine.
Key Customers
- Patients suffering from cancer and autoimmune diseases.
- Healthcare providers who prescribe and administer I-Mab's drugs.
- Pharmaceutical companies that partner with I-Mab to develop and commercialize its drugs.
- Hospitals and clinics that use I-Mab's therapies.
Financials
Chart & Info
I-Mab (IMAB) stock price: Price data unavailable
Latest News
-
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga · Jun 5, 2024
-
Stocks That Hit 52-Week Lows On Friday
benzinga · Sep 8, 2023
-
Stocks That Hit 52-Week Lows On Tuesday
benzinga · Aug 22, 2023
-
Stocks That Hit 52-Week Lows On Monday
benzinga · Aug 14, 2023
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for IMAB.
Price Targets
Wall Street price target analysis for IMAB.
MoonshotScore
What does this score mean?
The MoonshotScore rates IMAB's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Leadership: Xi-Yong Fu
CEO
Xi-Yong Fu is the CEO of I-Mab, leading a team of 32 employees. His background includes extensive experience in the biopharmaceutical industry, with a focus on drug development and commercialization. He has held leadership positions at several pharmaceutical companies, where he oversaw the development and launch of multiple successful products. His expertise spans various therapeutic areas, including oncology, immunology, and infectious diseases. He is known for his strategic vision and ability to build and lead high-performing teams.
Track Record: Under Xi-Yong Fu's leadership, I-Mab has made significant progress in advancing its pipeline of drug candidates through clinical trials. The company has established strategic collaborations with major pharmaceutical companies, validating its technology and providing access to resources and expertise. Key milestones include the completion of Phase 3 clinical trials for Eftansomatropin alfa and the advancement of Lemzoparlimab into Phase 2 clinical trials. His leadership has been instrumental in driving the company's growth and establishing its position as a leading biopharmaceutical company.
I-Mab ADR Information Sponsored
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company trading on U.S. stock exchanges. IMAB, as an ADR, allows U.S. investors to invest in I-Mab more conveniently without the complexities of cross-border transactions. Each IMAB ADR represents a specific number of I-Mab's ordinary shares traded on its home market.
- Home Market Ticker: Shanghai Stock Exchange, China
- ADR Level: 2
- ADR Ratio: 1:1
I-Mab Stock: Key Questions Answered
What does I-Mab do?
I-Mab is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative biologics for the treatment of cancer and autoimmune diseases. The company's pipeline includes multiple drug candidates in various stages of clinical development, targeting significant unmet medical needs. I-Mab leverages its proprietary drug development platform and strategic collaborations with pharmaceutical companies to accelerate the development and commercialization of its therapies. The company's mission is to bring transformative medicines to patients worldwide.
What do analysts say about IMAB stock?
Analyst coverage of IMAB is limited, reflecting its status as a clinical-stage biopharmaceutical company. However, analysts generally view the company's pipeline of drug candidates and strategic collaborations as positive factors. Key valuation metrics include the potential market size of its lead drug candidates and the likelihood of successful clinical trial outcomes and regulatory approvals. Growth considerations include the company's ability to secure additional funding and partnerships to support its research and development efforts. Analyst consensus is not available.
What are the main risks for IMAB?
The main risks for I-Mab include the inherent uncertainty in drug development, including the potential for clinical trial failures and regulatory setbacks. The company also faces competition from established pharmaceutical companies and emerging biotech firms. Changes in healthcare regulations and reimbursement policies could also impact the company's prospects. Additionally, economic downturns and market volatility could affect the company's ability to raise capital and fund its operations. As an ADR, I-Mab is also subject to currency risk.
How does I-Mab navigate regulatory approval processes?
I-Mab navigates regulatory approval processes by adhering to strict guidelines set by regulatory agencies such as the FDA and EMA. The company conducts rigorous clinical trials to demonstrate the safety and efficacy of its drug candidates. I-Mab also maintains close communication with regulatory agencies throughout the development process to address any concerns and ensure compliance. The company's regulatory strategy is tailored to each drug candidate and market, taking into account local regulations and requirements. Successful navigation of regulatory approval processes is critical for I-Mab to bring its therapies to market.
What is I-Mab's drug pipeline status?
I-Mab's drug pipeline includes multiple drug candidates in various stages of clinical development. Key programs include Felzartamab, a CD38 antibody in Phase 1b/2a trials for membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone that has completed Phase 3 clinical trials for pediatric growth hormone deficiency; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trials. The company also has several other promising drug candidates in earlier stages of development, targeting a range of oncology and autoimmune indications. Upcoming catalysts include data readouts from clinical trials and regulatory approval decisions.
What are the key factors to evaluate for IMAB?
I-Mab (IMAB) currently holds an AI score of 39/100, indicating low score. Key strength: Diverse pipeline of clinical-stage drug candidates.. Primary risk to monitor: Potential: Clinical trial failures and regulatory setbacks for drug candidates.. This is not financial advice.
How frequently does IMAB data refresh on this page?
IMAB prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven IMAB's recent stock price performance?
Recent price movement in I-Mab (IMAB) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Diverse pipeline of clinical-stage drug candidates.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- AI analysis is pending and may provide additional insights.